 Measurement of liver iron concentration LIC by MRI yields similar results to those coming from liver biopsy analysis, and is a validated tool for detection of iron overload. Data has been published from a multi-center trial evaluating the efficacy and safety of deferasirox DFX in low and intermediate-1 risk MDS patients with transfusion-dependent IOL and showed DFX yields sufficient reduction of excess iron indicated by serum ferritin levels and most importantly by liver MRI. But the median duration of DFX treatment is only 354 days and no data of Chinese patients was included. Most of the studies for MDS lack data of long term follow-up and there is scarcely any data on AA so far. 